BioMarin Pharmaceutical Inc. (BMRN) is highlighted as one of the most promising future stocks by Wall Street analysts, with a Buy rating and $86.00 price target from Barclays. The company reported fiscal Q2 2025 results, showing total revenues of $825 million, up 16% year-over-year and 17% at constant currency. GAAP diluted EPS was $1.23, up 124%, and non-GAAP diluted EPS was $1.44, up 50%.

BioMarin Pharmaceutical Inc. (BMRN) develops therapies for serious medical conditions and rare diseases, with products like Valoctocogene roxaparvovec, Vosoritide, and BMN 307 in its pipeline. While seen as a strong investment, other AI stocks are considered to offer greater upside potential with less downside risk. For more information on undervalued AI stocks, a free report is available.

A pharmaceutical plant is manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. The positive rating update for BioMarin Pharmaceutical Inc. (BMRN) follows the release of its fiscal Q2 2025 results, showcasing growth in total revenues and diluted EPS. Hedge funds are showing interest in small-cap healthcare stocks, including BMRN.

Read more at Yahoo Finance: Barclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86